CliffBio
small molecule

RELISTOR

METHYLNALTREXONE BROMIDE

Loss of exclusivityMarch 2031latest FDA-listed patent expiry
CompanySalix Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameRELISTOR
Active ingredientMETHYLNALTREXONE BROMIDE
Strength150MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2016
Marketing statusRX

Listed patents

PatentExpiresType
10307417March 2031product
8956651March 2031product
9314461March 2031product
10376505March 2031product
8524276March 2031product
9492445September 2029product
9724343September 2029product
8420663September 2029use U-1185
9180125September 2029product

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RELISTOR patent cliff — loss of exclusivity March 2031 | CliffBio